<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.1?>
<?ConverterInfo.XSLTName jp2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Bioinformatics</journal-id>
    <journal-id journal-id-type="iso-abbrev">Bioinformatics</journal-id>
    <journal-id journal-id-type="publisher-id">bioinformatics</journal-id>
    <journal-title-group>
      <journal-title>Bioinformatics</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1367-4803</issn>
    <issn pub-type="epub">1367-4811</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">7320600</article-id>
    <article-id pub-id-type="doi">10.1093/bioinformatics/btaa261</article-id>
    <article-id pub-id-type="publisher-id">btaa261</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Applications Notes</subject>
        <subj-group subj-group-type="category-toc-heading">
          <subject>Genome Analysis</subject>
        </subj-group>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>ShallowHRD: detection of homologous recombination deficiency from shallow whole genome sequencing</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3574-9911</contrib-id>
        <name>
          <surname>Eeckhoutte</surname>
          <given-names>Alexandre</given-names>
        </name>
        <xref ref-type="corresp" rid="btaa261-cor1"/>
        <xref ref-type="aff" rid="btaa261-aff1">b1</xref>
        <xref ref-type="aff" rid="btaa261-aff2">b2</xref>
        <!--<email>alexandre.eeckhoutte@curie.fr</email>-->
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Houy</surname>
          <given-names>Alexandre</given-names>
        </name>
        <xref ref-type="aff" rid="btaa261-aff1">b1</xref>
        <xref ref-type="aff" rid="btaa261-aff2">b2</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Manié</surname>
          <given-names>Elodie</given-names>
        </name>
        <xref ref-type="aff" rid="btaa261-aff1">b1</xref>
        <xref ref-type="aff" rid="btaa261-aff2">b2</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Reverdy</surname>
          <given-names>Manon</given-names>
        </name>
        <xref ref-type="aff" rid="btaa261-aff1">b1</xref>
        <xref ref-type="aff" rid="btaa261-aff2">b2</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Bièche</surname>
          <given-names>Ivan</given-names>
        </name>
        <xref ref-type="aff" rid="btaa261-aff3">b3</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Marangoni</surname>
          <given-names>Elisabetta</given-names>
        </name>
        <xref ref-type="aff" rid="btaa261-aff2">b2</xref>
        <xref ref-type="aff" rid="btaa261-aff4">b4</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Goundiam</surname>
          <given-names>Oumou</given-names>
        </name>
        <xref ref-type="aff" rid="btaa261-aff2">b2</xref>
        <xref ref-type="aff" rid="btaa261-aff4">b4</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Vincent-Salomon</surname>
          <given-names>Anne</given-names>
        </name>
        <xref ref-type="aff" rid="btaa261-aff5">b5</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Stoppa-Lyonnet</surname>
          <given-names>Dominique</given-names>
        </name>
        <xref ref-type="aff" rid="btaa261-aff1">b1</xref>
        <xref ref-type="aff" rid="btaa261-aff6">b6</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Bidard</surname>
          <given-names>François-Clément</given-names>
        </name>
        <xref ref-type="aff" rid="btaa261-aff7">b7</xref>
        <xref ref-type="aff" rid="btaa261-aff8">b8</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Stern</surname>
          <given-names>Marc-Henri</given-names>
        </name>
        <xref ref-type="aff" rid="btaa261-aff1">b1</xref>
        <xref ref-type="aff" rid="btaa261-aff2">b2</xref>
        <xref ref-type="aff" rid="btaa261-aff3">b3</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Popova</surname>
          <given-names>Tatiana</given-names>
        </name>
        <xref ref-type="aff" rid="btaa261-aff1">b1</xref>
        <xref ref-type="aff" rid="btaa261-aff2">b2</xref>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name>
          <surname>Birol</surname>
          <given-names>Inanc</given-names>
        </name>
        <role>Associate Editor</role>
      </contrib>
    </contrib-group>
    <aff id="btaa261-aff1"><label>b1</label><institution>DNA Repair and Uveal Melanoma (D.R.U.M.)</institution>, Inserm U830, Institut Curie, Paris 75248, <country country="FR">France</country></aff>
    <aff id="btaa261-aff2"><label>b2</label><institution>Institut Curie</institution>, PSL Research University, Paris 75005, <country country="FR">France</country></aff>
    <aff id="btaa261-aff3"><label>b3</label><institution>Department of Genetics</institution>, Institut Curie, Paris 75248, <country country="FR">France</country></aff>
    <aff id="btaa261-aff4"><label>b4</label><institution>Department of Translational Research</institution>, Institut Curie PSL Research University, Paris 75248, <country country="FR">France</country></aff>
    <aff id="btaa261-aff5"><label>b5</label><institution>Department of Biopathology</institution>, Institut Curie PSL Research University, Paris 75005, <country country="FR">France</country></aff>
    <aff id="btaa261-aff6"><label>b6</label><institution>Faculty of Medicine</institution>, University of Paris, Paris, <country country="FR">France</country></aff>
    <aff id="btaa261-aff7"><label>b7</label><institution>Department of Medical Oncology</institution>, Institut Curie PSL Research University, Paris 75248, <country country="FR">France</country></aff>
    <aff id="btaa261-aff8"><label>b8</label><institution>Versailles Saint Quentin en Yvelines University</institution>, Paris Saclay University, Versailles 78035, <country country="FR">France</country></aff>
    <author-notes>
      <corresp id="btaa261-cor1">To whom correspondence should be addressed. <email>alexandre.eeckhoutte@curie.fr</email></corresp>
    </author-notes>
    <pub-date pub-type="ppub">
      <day>15</day>
      <month>6</month>
      <year>2020</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2020-04-21">
      <day>21</day>
      <month>4</month>
      <year>2020</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>21</day>
      <month>4</month>
      <year>2020</year>
    </pub-date>
    <!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
    <volume>36</volume>
    <issue>12</issue>
    <fpage>3888</fpage>
    <lpage>3889</lpage>
    <history>
      <date date-type="received">
        <day>03</day>
        <month>1</month>
        <year>2020</year>
      </date>
      <date date-type="rev-recd">
        <day>25</day>
        <month>3</month>
        <year>2020</year>
      </date>
      <date date-type="accepted">
        <day>14</day>
        <month>4</month>
        <year>2020</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2020. Published by Oxford University Press.</copyright-statement>
      <copyright-year>2020</copyright-year>
      <license license-type="cc-by" xlink:href="http://creativecommons.org/licenses/by/4.0/">
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="btaa261.pdf"/>
    <abstract>
      <title>Abstract</title>
      <sec id="s1">
        <title>Summary</title>
        <p>We introduce <italic>shallowHRD</italic>, a software tool to evaluate tumor homologous recombination deficiency (HRD) based on whole genome sequencing (WGS) at low coverage (shallow WGS or sWGS; ∼1X coverage). The tool, based on mining copy number alterations profile, implements a fast and straightforward procedure that shows 87.5% sensitivity and 90.5% specificity for HRD detection. <italic>shallowHRD</italic> could be instrumental in predicting response to poly(ADP-ribose) polymerase inhibitors, to which HRD tumors are selectively sensitive. <italic>shallowHRD</italic> displays efficiency comparable to most state-of-art approaches, is cost-effective, generates low-storable outputs and is also suitable for fixed-formalin paraffin embedded tissues.</p>
      </sec>
      <sec id="s2">
        <title>Availability and implementation</title>
        <p><italic>shallowHRD</italic> R script and documentation are available at <ext-link ext-link-type="uri" xlink:href="https://github.com/aeeckhou/shallowHRD">https://github.com/aeeckhou/shallowHRD</ext-link>.</p>
      </sec>
      <sec id="s4">
        <title>Supplementary information</title>
        <p><xref ref-type="supplementary-material" rid="sup1">Supplementary data</xref> are available at <italic>Bioinformatics</italic> online.</p>
      </sec>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Ligue Nationale Contre le Cancer</institution>
          </institution-wrap>
        </funding-source>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="2"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec>
    <title>1 Introduction</title>
    <p>Aggressive subtypes of breast and ovarian cancers are frequently associated with homologous recombination deficiency (HRD) making these tumors sensitive to poly(ADP-ribose) polymerase inhibitors (<xref rid="btaa261-B4" ref-type="bibr">Coleman <italic>et al.</italic>, 2019</xref>). HRD arises upon inactivation of <italic>BRCA1/2</italic>, <italic>RAD51C</italic> or <italic>PALB2</italic> and is characterized by specific tumor genome instability (<xref rid="btaa261-B8" ref-type="bibr">Nik-Zainal <italic>et al.</italic>, 2016</xref>; <xref rid="btaa261-B11" ref-type="bibr">Staaf <italic>et al.</italic>, 2019</xref>). Even though HRD genes are mostly known, exhaustive testing of their inactivation is difficult. This motivates developing surrogate genomic markers of HRD. Recent developments based on high throughput sequencing, HRDetect, Signature 3, SigMA, scarHRD, achieved excellent capacity to evaluate HRD (<xref rid="btaa261-B5" ref-type="bibr">Davies <italic>et al.</italic>, 2017</xref>; <xref rid="btaa261-B7" ref-type="bibr">Gulhan <italic>et al.</italic>, 2019</xref>; <xref rid="btaa261-B9" ref-type="bibr">Polak <italic>et al.</italic>, 2017</xref>; <xref rid="btaa261-B12" ref-type="bibr">Sztupinszki <italic>et al.</italic>, 2018</xref>). However, these methods are technically complex, time- and data-storage consuming, often need a matched normal sample and can be costly.</p>
    <p>We introduce <italic>shallowHRD</italic>, a software for HRD testing based on the number of large-scale genomic alterations (LGA) obtained from whole genome sequencing (WGS) at low coverage (shallow WGS or sWGS; ∼1X). sWGS robustly detect copy number alterations (CNAs), even in fixed-formalin paraffin embedded (FFPE) samples and liquid biopsies (<xref rid="btaa261-B13" ref-type="bibr">Van Roy <italic>et al.</italic>, 2017</xref>) at low cost and with easy-storable outputs. The concept of LGAs follows single-nucleotide polymorphism (SNP) array approaches, exploiting an increased number of large-scale intra-chromosomal CNAs characteristic of HRD (<xref rid="btaa261-B1" ref-type="bibr">Abkevich <italic>et al.</italic>, 2012</xref>; <xref rid="btaa261-B2" ref-type="bibr">Birkbak <italic>et al.</italic>, 2012</xref>; <xref rid="btaa261-B10" ref-type="bibr">Popova <italic>et al.</italic>, 2012</xref>).</p>
  </sec>
  <sec>
    <title>2 Materials and methods</title>
    <sec>
      <title>2.1 Data</title>
      <p>In-house sWGS of breast and ovarian cancers (26 primary tumors, 39 patient-derived xenografts from frozen blocks and 4 primary tumors FFPE) and down-sampled to ∼1X WGS (108 normal tissues, 79 primary tumors from the TCGA breast cancer) were processed by Control-FREEC (v11.5) (<xref rid="btaa261-B3" ref-type="bibr">Boeva <italic>et al.</italic>, 2012</xref>) (<xref ref-type="supplementary-material" rid="sup1">Supplementary Material</xref>).</p>
    </sec>
    <sec>
      <title>2.2 shallowHRD</title>
      <p>The tool takes as input ‘<italic>sample_name</italic>.bam_ratio.txt’, which includes CNA profile <inline-formula id="IE1"><mml:math id="IM1"><mml:msub><mml:mrow><mml:mo>{</mml:mo><mml:mi>x</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="normal"> </mml:mi><mml:mi>g</mml:mi><mml:mo>}</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:mi>N</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> where <italic>x</italic> is normalized read counts in a sliding window, <inline-formula id="IE2"><mml:math id="IM2"><mml:mi>g</mml:mi></mml:math></inline-formula> is genomic coordinate and the profile segmentation with <italic>S<sub>i</sub></italic>, <italic>Z<sub>i</sub></italic> segment median and size (in megabases, Mb).</p>
      <sec>
        <title>2.2.1 Workflow </title>
        <list list-type="roman-lower">
          <list-item>
            <p><inline-formula id="IE3"><mml:math id="IM3"><mml:mtext>CNA</mml:mtext><mml:mo> </mml:mo><mml:mtext>cut</mml:mtext><mml:mo>-</mml:mo><mml:mtext>off</mml:mtext></mml:math></inline-formula> is detected and the profile segmentation is optimized as follows: Segments are defined as ‘large’ if <inline-formula id="IE4"><mml:math id="IM4"><mml:msub><mml:mrow><mml:mi>Z</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>≥</mml:mo><mml:mo>(</mml:mo><mml:mi>Q</mml:mi><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>Q</mml:mi><mml:mn>3</mml:mn><mml:mo>)</mml:mo><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:math></inline-formula>, where <inline-formula id="IE5"><mml:math id="IM5"><mml:mi>Q</mml:mi><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi mathvariant="normal"> </mml:mi><mml:mi>Q</mml:mi><mml:mn>3</mml:mn></mml:math></inline-formula> are quartiles of <italic>Z<sub>i</sub></italic> (<italic>Z<sub>i</sub></italic> &gt; 3 Mb) distribution. <italic>M</italic> is detected as the first local minimum of <inline-formula id="IE6"><mml:math id="IM6"><mml:mfenced open="|" close="|" separators="|"><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:math></inline-formula> density, where <italic>i</italic>, <italic>j</italic> are large segments (<xref ref-type="supplementary-material" rid="sup1">Supplementary Fig. S1</xref>). <inline-formula id="IE7"><mml:math id="IM7"><mml:mi mathvariant="normal">CNA</mml:mi><mml:mi mathvariant="normal"> </mml:mi><mml:mtext>cut</mml:mtext><mml:mo>-</mml:mo><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mo>=</mml:mo><mml:mi mathvariant="normal"> </mml:mi><mml:mi mathvariant="normal">min</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi mathvariant="normal">max</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mn>0.025</mml:mn><mml:mo>,</mml:mo><mml:mi mathvariant="normal"> </mml:mi><mml:mi>M</mml:mi></mml:mrow></mml:mfenced><mml:mo>,</mml:mo><mml:mi mathvariant="normal"> </mml:mi><mml:mn>0.45</mml:mn></mml:mrow></mml:mfenced></mml:math></inline-formula>. Adjacent segments are merged if <inline-formula id="IE8"><mml:math id="IM8"><mml:mfenced open="|" close="|" separators="|"><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced><mml:mo>&lt;</mml:mo><mml:mtext>CNA</mml:mtext><mml:mo> </mml:mo><mml:mtext>cut</mml:mtext><mml:mo>-</mml:mo><mml:mtext>off</mml:mtext></mml:math></inline-formula>; starting from the largest segment.</p>
          </list-item>
          <list-item>
            <p>LGAs, defined as intra-chromosome arm CNA breaks with adjacent segments <inline-formula id="IE9"><mml:math id="IM9"><mml:msub><mml:mrow><mml:mi>Z</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>Z</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>≥</mml:mo><mml:mn>10</mml:mn><mml:mi mathvariant="normal"> </mml:mi></mml:math></inline-formula>Mb, are counted after removing segments &lt;3 Mb.</p>
          </list-item>
          <list-item>
            <p>The sample is annotated as ‘non-HRD’ (LGA &lt; 15), ‘borderline’ (15 ≤ LGA ≤ 19) or ‘HRD’ (LGA &gt; 19).</p>
          </list-item>
          <list-item>
            <p>Sample quality is defined by <italic>M</italic> and <italic>cMAD</italic>, <inline-formula id="IE10"><mml:math id="IM10"><mml:mi mathvariant="italic">cMAD</mml:mi><mml:mi mathvariant="normal"> </mml:mi><mml:mo>=</mml:mo><mml:mi mathvariant="normal">median</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mfenced open="|" close="|" separators="|"><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mi>x</mml:mi><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:math></inline-formula>, where <inline-formula id="IE11"><mml:math id="IM11"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> corresponds to the segment enclosing <italic>x</italic>, before optimization: ‘bad’ (<italic>cMAD</italic> &gt; 0.5 | <italic>cMAD</italic> &gt; 0.14 and <italic>M</italic> &gt; 0.45), ‘average’ (<italic>cMAD</italic> &gt; 0.14 and <italic>M</italic> &lt; 0.45 | <italic>cMAD</italic> &lt; 0.14 and <italic>M</italic> &gt; 0.45) or ‘normal or highly contaminated’ (<italic>M</italic> &lt; 0.025) (<xref ref-type="supplementary-material" rid="sup1">Supplementary Material and Fig. S2</xref>).</p>
          </list-item>
          <list-item>
            <p><italic>CCNE1</italic> amplification is called if <inline-formula id="IE12"><mml:math id="IM12"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mo>≥</mml:mo><mml:mn>4</mml:mn><mml:mo>·</mml:mo><mml:mtext>CNA</mml:mtext><mml:mo> </mml:mo><mml:mtext>cut</mml:mtext><mml:mo>-</mml:mo><mml:mtext>off</mml:mtext></mml:math></inline-formula>, where <italic>c</italic> is the segment enclosing the gene (4 was set arbitrarily).</p>
          </list-item>
        </list>
        <p><italic>shallowHRD</italic> output contains: (A) Tumor genome profile. (B) Density plot for <inline-formula id="IE13"><mml:math id="IM13"><mml:mtext>CNA</mml:mtext><mml:mo> </mml:mo><mml:mtext>cut</mml:mtext><mml:mo>-</mml:mo><mml:mtext>off</mml:mtext></mml:math></inline-formula>. (C) CNA segmentation summary. (D) Sample quality and HRD diagnostics (<xref ref-type="supplementary-material" rid="sup1">Supplementary Fig. S3</xref>).</p>
      </sec>
    </sec>
  </sec>
  <sec>
    <title>3 Results</title>
    <p>In-house sWGS and down-sampled WGS of normal samples (TCGA) were employed to develop the sWGS methodology similar to the large-scale state transitions (LST) in SNP-arrays (<xref rid="btaa261-B10" ref-type="bibr">Popova <italic>et al.</italic>, 2012</xref>) (Section 2). LGAs inferred from sWGS corresponded well to the LSTs with identical HRD calls for 8 primary tumors tested (76–97% match in segments<inline-formula id="IE14"><mml:math id="IM14"><mml:mi mathvariant="normal"> </mml:mi><mml:mo>≥</mml:mo></mml:math></inline-formula> 10 Mb) (<xref ref-type="supplementary-material" rid="sup1">Supplementary Fig. S4</xref>). sWGS coverage &gt;0.3X provide adequate quality, also for FFPE (<xref ref-type="supplementary-material" rid="sup1">Supplementary Figs. S2 and 5</xref>).</p>
    <p>Validation by down-sampled WGS (TCGA) showed LGA to be coherent to SNP-arrays LST (<italic>r</italic> = 0.92; slope = 0.88; <italic>P</italic> &lt; 2.2e–16, Pearson) with increased discrepancy in average quality samples (<italic>n</italic> = 13), and HRD diagnostics discordant in three and borderline in four cases (<xref ref-type="fig" rid="btaa261-F1">Fig. 1A;</xref><xref ref-type="supplementary-material" rid="sup1">Supplementary Material, Supplementary Figs. S6 and 7</xref>, <xref ref-type="supplementary-material" rid="sup1">Supplementary Table S1</xref>). <italic>CCNE1</italic> amplification was found in four non-HRD cases, in-line with previous observations of almost mutual exclusivity with HRD (<xref rid="btaa261-B6" ref-type="bibr">Goundiam <italic>et al.</italic>, 2015</xref>). Thus, sWGS LGAs is suitable to take over the SNP-array LSTs, which is a clinically validated method for HRD detection.</p>
    <fig id="btaa261-F1" orientation="portrait" position="float">
      <label>Fig. 1.</label>
      <caption>
        <p><italic>shallowHRD</italic> validation in down-sampled WGS of the TCGA (<bold>A</bold>) and performance (<bold>B</bold>). Proven/No HRD: cases with/without inactivation of <italic>BRCA1/2</italic>, <italic>RAD51C</italic> or <italic>PALB2</italic> (<xref ref-type="supplementary-material" rid="sup1">Supplementary Material</xref>); HRD (red) and non-HRD (blue) cases in SNP-arrays; LGAs: large-scale genomic alterations; WES: whole exome sequencing. <sup>a</sup>Low specificity could be due to non-complete annotation of HRD </p>
      </caption>
      <graphic xlink:href="btaa261f1"/>
    </fig>
    <p>Tumor content for sWGS limits to &gt;0.3 as estimated from the TCGA and <italic>in silico</italic> dilution series (<xref ref-type="supplementary-material" rid="sup1">Supplementary Material, Supplementary Figs. S8 and 9</xref>).</p>
    <p>Fifteen and 20 LGAs represent soft and stringent cut-offs with sensitivity of 87.5% and 81.25% (16 cases HRD) and specificity of 90.5% and 95.2% (63 non-HRD cases), respectively, which is compatible with other state-of-the-art approaches (<xref ref-type="fig" rid="btaa261-F1">Fig. 1B</xref>).</p>
    <p>To conclude, <italic>shallowHRD</italic> implements a fast and straightforward evaluation of tumor HRD in breast, ovarian and other cancers such as pancreatic or prostatic, performing similar to most state-of-the-art approaches, the technique is cheap and suitable for all type of samples.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data" id="sup1">
      <label>btaa261_Supplementary_Data</label>
      <media xlink:href="btaa261_supplementary_data.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ack1">
    <title>Acknowledgements</title>
    <p>The results here are in part-based upon data generated by the TCGA Research Network: <ext-link ext-link-type="uri" xlink:href="http://cancergenome.nih.gov/">http://cancergenome.nih.gov/</ext-link>. The authors thank The Seven Bridges Cancer Genomics Cloud for computational facilities.</p>
    <sec>
      <title>Funding</title>
      <p>This work was supported by the Ligue Nationale Contre le Cancer (to A.E.). </p>
      <p>
        <italic>Conflict of Interest:</italic>
      </p>
      <p>E. Manié, T. Popova and M.-H. Stern are co-inventors of the LST method (US20170260588, US20150140122 and exclusive Licence to Myriad Genetics). </p>
    </sec>
  </ack>
  <ref-list id="ref1">
    <title>References</title>
    <ref id="btaa261-B1">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abkevich</surname><given-names>V.</given-names></name></person-group><etal>et al</etal> (<year>2012</year>) 
<article-title>Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer</article-title>. <source>Br. J. Cancer</source>, <volume>107</volume>, <fpage>1776</fpage>–<lpage>1782</lpage>.<pub-id pub-id-type="pmid">23047548</pub-id></mixed-citation>
    </ref>
    <ref id="btaa261-B2">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Birkbak</surname><given-names>N.J.</given-names></name></person-group><etal>et al</etal> (<year>2012</year>) 
<article-title>Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents</article-title>. <source>Cancer Discov</source>., <volume>2</volume>, <fpage>366</fpage>–<lpage>375</lpage>.<pub-id pub-id-type="pmid">22576213</pub-id></mixed-citation>
    </ref>
    <ref id="btaa261-B3">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boeva</surname><given-names>V.</given-names></name></person-group><etal>et al</etal> (<year>2012</year>) 
<article-title>Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data</article-title>. <source>Bioinformatics</source>, <volume>28</volume>, <fpage>423</fpage>–<lpage>425</lpage>.<pub-id pub-id-type="pmid">22155870</pub-id></mixed-citation>
    </ref>
    <ref id="btaa261-B4">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coleman</surname><given-names>R.L.</given-names></name></person-group><etal>et al</etal> (<year>2019</year>) 
<article-title>Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer</article-title>. <source>N. Engl. J. Med</source>., <volume>381</volume>, <fpage>2403</fpage>–<lpage>2415</lpage>.<pub-id pub-id-type="pmid">31562800</pub-id></mixed-citation>
    </ref>
    <ref id="btaa261-B5">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davies</surname><given-names>H.</given-names></name></person-group><etal>et al</etal> (<year>2017</year>) 
<article-title>HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures</article-title>. <source>Nat. Med</source>., <volume>23</volume>, <fpage>517</fpage>–<lpage>525</lpage>.<pub-id pub-id-type="pmid">28288110</pub-id></mixed-citation>
    </ref>
    <ref id="btaa261-B6">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goundiam</surname><given-names>O.</given-names></name></person-group><etal>et al</etal> (<year>2015</year>) 
<article-title>Histo-genomic stratification reveals the frequent amplification/overexpression of CCNE1 and BRD4 genes in non-BRCAness high grade ovarian carcinoma</article-title>. <source>Int. J. Cancer</source>, <volume>137</volume>, <fpage>1890</fpage>–<lpage>1900</lpage>.<pub-id pub-id-type="pmid">25892415</pub-id></mixed-citation>
    </ref>
    <ref id="btaa261-B7">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gulhan</surname><given-names>D.C.</given-names></name></person-group><etal>et al</etal> (<year>2019</year>) 
<article-title>Detecting the mutational signature of homologous recombination deficiency in clinical samples</article-title>. <source>Nat. Genet</source>., <volume>51</volume>, <fpage>912</fpage>–<lpage>919</lpage>.<pub-id pub-id-type="pmid">30988514</pub-id></mixed-citation>
    </ref>
    <ref id="btaa261-B8">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nik-Zainal</surname><given-names>S.</given-names></name></person-group><etal>et al</etal> (<year>2016</year>) 
<article-title>Landscape of somatic mutations in 560 breast cancer whole-genome sequences</article-title>. <source>Nature</source>, <volume>534</volume>, <fpage>47</fpage>–<lpage>54</lpage>.<pub-id pub-id-type="pmid">27135926</pub-id></mixed-citation>
    </ref>
    <ref id="btaa261-B9">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polak</surname><given-names>P.</given-names></name></person-group><etal>et al</etal> (<year>2017</year>) 
<article-title>A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer</article-title>. <source>Nat. Genet</source>., <volume>49</volume>, <fpage>1476</fpage>–<lpage>1486</lpage>.<pub-id pub-id-type="pmid">28825726</pub-id></mixed-citation>
    </ref>
    <ref id="btaa261-B10">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Popova</surname><given-names>T.</given-names></name></person-group><etal>et al</etal> (<year>2012</year>) 
<article-title>Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation</article-title>. <source>Cancer Res</source>., <volume>72</volume>, <fpage>5454</fpage>–<lpage>5462</lpage>.<pub-id pub-id-type="pmid">22933060</pub-id></mixed-citation>
    </ref>
    <ref id="btaa261-B11">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Staaf</surname><given-names>J.</given-names></name></person-group><etal>et al</etal> (<year>2019</year>) 
<article-title>Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study</article-title>. <source>Nat. Med</source>., <volume>25</volume>, <fpage>1526</fpage>–<lpage>1533</lpage>.<pub-id pub-id-type="pmid">31570822</pub-id></mixed-citation>
    </ref>
    <ref id="btaa261-B12">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sztupinszki</surname><given-names>Z.</given-names></name></person-group><etal>et al</etal> (<year>2018</year>) 
<article-title>Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer</article-title>. <source>NPJ Breast Cancer</source>, <volume>4</volume>, <fpage>16</fpage>.<pub-id pub-id-type="pmid">29978035</pub-id></mixed-citation>
    </ref>
    <ref id="btaa261-B13">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Roy</surname><given-names>N.</given-names></name></person-group><etal>et al</etal> (<year>2017</year>) 
<article-title>Shallow whole genome sequencing on circulating cell-free DNA allows reliable noninvasive copy-number profiling in neuroblastoma patients</article-title>. <source>Clin. Cancer Res</source>., <volume>23</volume>, <fpage>6305</fpage>–<lpage>6314</lpage>.<pub-id pub-id-type="pmid">28710315</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
